This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coukos, G. Articles by Molnar-Kimber, K. L. Search for Related Content PubMed PubMed Citation Articles by Coukos, G. Articles by Molnar-Kimber, K. L.

Oncolytic Herpes Simplex Virus-1 Lacking ICP34.5 Induces p53-independent Death and Is Efficacious against Chemotherapy-resistant Ovarian Cancer¹

Divisions of Gynecologic Oncology [G. C., S. C. R.] and Reproductive Biology [A. M.], Department of Obstetrics and Gynecology; Division of Pulmonary Medicine/Critical Care [S. M. A.], Department of Medicine; and the Thoracic Oncology Laboratory, Department of Surgery [E. K., K. L. M-K.], University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104

Replication-restricted herpes simplex virus-1 (HSV-1) strains lacking ICP34.5 are emerging as powerful anticancer agents against several solid tumors including epithelial ovarian cancer (EOC). Although chemotherapy-resistant tumors would be likely candidates for treatment with HSV-1 mutants lacking ICP34.5, the efficacy of these mutants on such tumors is unknown. In the present study, we investigated whether chemotherapy resistance affects the response of ovarian cancer cells to HSV-R3616, an ICP34.5-deficient, replication-restricted HSV-1. Primary EOC cultures obtained from patients who varied in their responses to platinum/paclitaxel induction chemotherapy displayed similar sensitivity to HSV-R3616. Similarly, chemotherapy-sensitive ovarian cancer cells A2780 and PA-1, possessing wild-type p53, and their respective chemotherapy-resistant clones A2780/200CP, lacking p53 function, and PA-1/E6, permanently expressing the HPV E6 gene, were equally sensitive to HSV oncolysis. Because wild-type HSV can kill cells by apoptosis and nonapoptotic mechanisms, we investigated the involvement of apoptosis and the role of the p53 tumor suppressor gene in oncolysis induced by HSV-R3616. Infection of ovarian cancer cell lines by HSV-R3616 was followed by cell death via apoptosis or nonapoptotic mechanisms as noted by morphology, cell cycle analysis, and in situ TUNEL assay. p53 protein levels remained unchanged, and Bax protein levels decreased in cells possessing intact p53 and that mainly underwent HSV-induced apoptosis. Loss of p53 function did not affect the frequency or rate of apoptosis or the sensitivity of EOC cells to the oncolytic effect of HSV-R3616. These results suggest that recombinant HSV-1 lacking ICP34.5 is capable of killing ovarian cancer cells that lack p53 function, resist apoptosis, and/or are chemotherapy resistant. These data support the hypothesis that HSV-based oncolytic therapy may be efficacious in chemotherapy-resistant tumors, including tumors that are deficient in p53.

This article has been cited by other articles:

				Y.-Y. Huang, Z. Yu, S.-F. Lin, S. Li, Y. Fong, and R. J. Wong Nectin-1 Is a Marker of Thyroid Cancer Sensitivity to Herpes Oncolytic Therapy J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1965 - 1970. [Abstract] [Full Text] [PDF]

				Z. Yu, M.-K. Chan, P. O-charoenrat, D. P. Eisenberg, J. P. Shah, B. Singh, Y. Fong, and R. J. Wong Enhanced Nectin-1 Expression and Herpes Oncolytic Sensitivity in Highly Migratory and Invasive Carcinoma Clin. Cancer Res., July 1, 2005; 11(13): 4889 - 4897. [Abstract] [Full Text] [PDF]

				J. T. Mullen and K. K. Tanabe Viral Oncolysis Oncologist, April 1, 2002; 7(2): 106 - 119. [Abstract] [Full Text] [PDF]